Advertisement
NONOF vs NVO
Which Stock Would AI Choose? Novo Nordisk A/S (NONOF) vs. Novo Nordisk A/S (NVO) Stock Comparison
Key Takeaways
- Both NONOF and NVO provide exposure to Novo Nordisk A/S, a global leader in diabetes and obesity care with flagship products like Ozempic and Wegovy.
- Fundamentals are nearly identical, including a trailing P/E ratio (price-to-earnings ratio) around 12, EPS (earnings per share) of $3.61, and profit margins exceeding 33%.
- NVO offers superior liquidity on the NYSE with daily volumes over 25 million shares, compared to NONOF's low OTC volume of around 200 shares.
- Year-to-date gains are comparable at approximately 12% for NONOF and 11% for NVO, following pullbacks from 52-week highs near $82.
- Recent catalysts include U.S. rollout of oral Ozempic and new clinical trials for semaglutide, supporting long-term growth in obesity treatments.
- Traders may prefer NVO for accessibility, while NONOF suits those seeking direct Series B share exposure.
Introduction
NONOF and NVO both track Novo Nordisk A/S, the Danish pharmaceutical giant dominating diabetes and obesity markets with GLP-1 therapies like Ozempic and Wegovy. This comparison highlights differences in their U.S. listings—OTC Pink Sheets for NONOF versus NYSE American Depositary Receipts (ADRs) for NVO—amid recent market volatility. Investors and traders evaluating liquidity, trading costs, and accessibility in the current environment, especially with ongoing GLP-1 demand and competitive pressures, will find this analysis useful for relative performance insights and stock positioning.
NONOF Overview and Recent Performance
Novo Nordisk A/S, through its NONOF listing on OTC markets, focuses on pharmaceutical innovation in obesity/diabetes care and rare diseases. The company develops treatments like semaglutide-based drugs and growth hormone therapies, operating globally with strong profitability (operating margin ~45%). In recent market activity, NONOF has traded around $43.40, down from 52-week highs above $82 amid broader sector rotations and competition concerns. Low trading volume (~200 shares daily) contributes to wider spreads, influencing sentiment among retail traders. Key developments, such as pipeline expansions, provide stability, but illiquidity tempers momentum compared to major exchange peers.
NVO Overview and Recent Performance
NVO, the NYSE ADR for Novo Nordisk A/S, mirrors the company's business in diabetes/obesity products and rare disease therapies, with identical segments and high margins (profit margin 33%). Shares recently closed at $43.88, reflecting a similar pullback from peaks near $81 in recent weeks, driven by market shifts and GLP-1 sector news like generic approvals elsewhere. High volume (over 25 million shares) supports robust liquidity, bolstering institutional interest. Positive sentiment stems from U.S. Ozempic pill launches and semaglutide trials, though valuation pressures persist.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the top 25 AI trading bots curated from over 351 available bots that trade thousands of tickers across diverse strategies, timeframes, and styles. These trending bots excel in current conditions, posting annualized returns from +23.53% to +163.10%, win rates of 51.30% to 88.33%, profit factors up to 11.70, and profit-to-drawdown ratios reaching 17.02. Focused on high-momentum sectors like semiconductors, AI, space, and commodities, they feature average trade durations from 1 day to 49 days and absolute profits up to $48,782. Explore these high-performing options to enhance your trading with data-driven automation.
Head-to-Head Comparison
Both NONOF and NVO share Novo Nordisk's business model centered on GLP-1 agonists for obesity/diabetes growth, rare disease stability, and a beta under 0.4 indicating low volatility. Recent momentum shows parallel declines in recent weeks, with YTD gains in the low teens, pressured by rivals like Eli Lilly and regulatory news on generics. NVO edges in liquidity and accessibility for U.S. investors, reducing execution risks, while NONOF offers direct B-share exposure but higher spreads. Sector risks include patent cliffs and manufacturing constraints, balanced by pipeline catalysts; market sentiment favors liquid names amid volatility.
Tickeron AI Verdict
Tickeron's AI models currently favor NVO over NONOF, citing superior liquidity, higher trading volume, and broader institutional participation for consistent trend execution. While fundamentals align perfectly, NVO's NYSE positioning enhances relative stability and access to catalysts like Ozempic expansions, positioning it better probabilistically in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To understand the difference between Novo Nordisk - Ordinary Shares - Class B (NONOF) vs. Novo Nordisk - ADR (NVO) it is enough to know the definitions of Ordinary Shares - Class B and ADR
Ordinary Shares - Class B - Generally, Class B shares are issued by a company as a common stock with fewer voting rights and lower dividend priority than Class A shares. Class B may also have lower repayment priority in the event of a bankruptcy.
ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NONOF’s FA Score shows that 2 FA rating(s) are green whileNVO’s FA Score has 2 green FA rating(s).
- NONOF’s FA Score: 2 green, 3 red.
- NVO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NONOF’s TA Score shows that 5 TA indicator(s) are bullish while NVO’s TA Score has 5 bullish TA indicator(s).
- NONOF’s TA Score: 5 bullish, 3 bearish.
- NVO’s TA Score: 5 bullish, 4 bearish.
Price Growth
NONOF (@Pharmaceuticals: Major) experienced а +2.91% price change this week, while NVO (@Pharmaceuticals: Major) price change was +4.75% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.08%. For the same industry, the average monthly price growth was -0.45%, and the average quarterly price growth was +3.09%.
Reported Earning Dates
NVO is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| NONOF | NVO | NONOF / NVO | |
| Capitalization | 209B | 207B | 101% |
| EBITDA | 180B | 180B | 100% |
| Gain YTD | -9.892 | -4.396 | 225% |
| P/E Ratio | 10.66 | 10.90 | 98% |
| Revenue | 328B | 328B | 100% |
| Total Cash | 21.6B | 21.6B | 100% |
| Total Debt | 146B | 146B | 100% |
NONOF | NVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 92 | 88 | |
SMR RATING 1..100 | 16 | 16 | |
PRICE GROWTH RATING 1..100 | 52 | 50 | |
P/E GROWTH RATING 1..100 | 90 | 90 | |
SEASONALITY SCORE 1..100 | 22 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NONOF's Valuation (9) in the null industry is in the same range as NVO (10) in the Pharmaceuticals Major industry. This means that NONOF’s stock grew similarly to NVO’s over the last 12 months.
NVO's Profit vs Risk Rating (88) in the Pharmaceuticals Major industry is in the same range as NONOF (92) in the null industry. This means that NVO’s stock grew similarly to NONOF’s over the last 12 months.
NVO's SMR Rating (16) in the Pharmaceuticals Major industry is in the same range as NONOF (16) in the null industry. This means that NVO’s stock grew similarly to NONOF’s over the last 12 months.
NVO's Price Growth Rating (50) in the Pharmaceuticals Major industry is in the same range as NONOF (52) in the null industry. This means that NVO’s stock grew similarly to NONOF’s over the last 12 months.
NVO's P/E Growth Rating (90) in the Pharmaceuticals Major industry is in the same range as NONOF (90) in the null industry. This means that NVO’s stock grew similarly to NONOF’s over the last 12 months.
| NONOF | NVO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 66% | 2 days ago 51% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 61% |
| Momentum ODDS (%) | 3 days ago 75% | 2 days ago 68% |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 2 days ago 75% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 65% |
| Advances ODDS (%) | 3 days ago 75% | 2 days ago 67% |
| Declines ODDS (%) | N/A | 15 days ago 64% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 48% |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 62% |
Advertisement
NONOF and
Correlation & Price change
A.I.dvisor indicates that over the last year, NONOF has been closely correlated with NVO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NONOF jumps, then NVO could also see price increases.
| Ticker / NAME | Correlation To NONOF | 1D Price Change % | ||
|---|---|---|---|---|
| NONOF | 100% | -0.37% | ||
| NVO - NONOF | 70% Closely correlated | +1.29% | ||
| LABFF - NONOF | 23% Poorly correlated | N/A | ||
| IMRN - NONOF | 22% Poorly correlated | -3.49% | ||
| QSI - NONOF | 21% Poorly correlated | +2.44% | ||
| VRTX - NONOF | 21% Poorly correlated | +3.01% | ||
More | ||||